読み込み中
PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations. PRF-110 is presently undergoing assessment in two pivotal Phase 3 clinical trials, specifically for individuals recovering from bunionectomy and hernia repair procedures. The company, which was originally incorporated in 2007 under the name PainReform Ltd., maintains its headquarters in Tel Aviv, Israel.
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新データ
$0.8789
+$0.0202 · +2.35%
前日終値
$0.8789
+$0.0202 · +2.35%
日中の時刻はETです。市場データは遅延する場合があります。
PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations. PRF-110 is presently undergoing assessment in two pivotal Phase 3 clinical trials, specifically for individuals recovering from bunionectomy and hernia repair procedures. The company, which was originally incorporated in 2007 under the name PainReform Ltd., maintains its headquarters in Tel Aviv, Israel.
日中レンジ
現在 $0.8789
52週レンジ
現在 $0.8789
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
43
適正価値
センチメント
59
まちまち
リスク
69
高リスク
モメンタム
19
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations. PRF-110 is presently undergoing assessment in two pivotal Phase 3 clinical trials, specifically for individuals recovering from bunionectomy and hernia repair procedures. The company, which was originally incorporated in 2007 under the name PainReform Ltd., maintains its headquarters in Tel Aviv, Israel.
日中レンジ
現在 $0.8789
52週レンジ
現在 $0.8789
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1.7万 USD | — | — | 8.6万 USD | — |
| 売上原価 | 84.4万 USD | 1.6万 USD | 1.5万 USD | 1.5万 USD | 7000 USD |
| 粗利益 | −82.7万 USD | −1.6万 USD | −1.5万 USD | 7.1万 USD | −7000 USD |
| 研究開発 | 113.6万 USD | 1170.5万 USD | 603.5万 USD | 442.2万 USD | 286万 USD |
| 販売・一般管理 | 302.4万 USD | 295.2万 USD | 354.9万 USD | 444.7万 USD | 434.8万 USD |
| 営業費用 | 416万 USD | 1465.7万 USD | 958.4万 USD | 886.9万 USD | 720.8万 USD |
| 受取利息 | 12万 USD | 10.1万 USD | 40.6万 USD | 16万 USD | — |
| 支払利息 | 1万 USD | 1.4万 USD | 38.4万 USD | 6.1万 USD | 1万 USD |
| 減価償却費と償却費 | 77.4万 USD | 1.6万 USD | 1.5万 USD | 1.5万 USD | 7000 USD |
| 営業利益 | −498.7万 USD | −1467.3万 USD | −958.4万 USD | −886.9万 USD | −720.8万 USD |
| 純利益 | −483.8万 USD | −1458.8万 USD | −934.4万 USD | −879.2万 USD | −724.6万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
